Abatacept in difficult-to-treat juvenile idiopathic arthritis
Jasmin B Kuemmerle-Deschner1, SM Benseler21Pediatric Rheumatology Clinics, Dept of Pediatrics, University Hospital Tübingen, Germany; 2Dept of Pediatric Rheumatology, The Hospital for Sick Children, Toronto, CanadaAbstract: Juvenile idiopathic arthritis (JIA) is the most common chronic...
Guardado en:
Autores principales: | Jasmin B Kuemmerle-Deschner, SM Benseler |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/75fa9ca6eb904d318c615cc567d7e322 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Challenges in the management of juvenile idiopathic arthritis with etanercept
por: Clare E Pain, et al.
Publicado: (2009) -
Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
por: Mathieu S, et al.
Publicado: (2013) -
A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations
por: Wells AF, et al.
Publicado: (2014) -
Psycho-emotional condition of young adults with juvenile idiopathic arthritis
por: M.B. Dzhus
Publicado: (2017) -
Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences
por: Matthew L Stoll, et al.
Publicado: (2008)